AURX (Nuo Therapeutics) Interest Expense: $-0.18 Mil (TTM As of Mar. 2026)

What is Nuo Therapeutics Interest Expense?

Nuo Therapeutics AURX 33 Interest Expense is $-0.18 Mil as of Mar. 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.28 (Possible Value Trap). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nuo Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.18 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.18 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nuo Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -0.45 Mil. Nuo Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.18 Mil. Nuo Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nuo Therapeutics (OTCPK:AURX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nuo Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.18 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-0.45 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $1.03 Mil.

Nuo Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Nuo Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Nuo Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Nuo Therapeutics's Interest Expense can be seen below:

Nuo Therapeutics Interest Expense Chart

Nuo Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

-0.00

0.00

-0.00

Nuo Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.00	0.00	0.00	-0.00	-0.18

33GF Score

Nuo Therapeutics Inc AURX

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nuo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-0.18 Mil mean?

Nuo Therapeutics (AURX) has a Interest Expense of $-0.18 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nuo Therapeutics and its competitors.

Is Nuo Therapeutics' Interest Expense too high?

Nuo Therapeutics' current Interest Expense is $-0.18 Mil. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Nuo Therapeutics' Interest Expense compare to PDSB and LTRN?

Nuo Therapeutics' Interest Expense of $-0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current Interest Expense is $-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nuo Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.28, compared to a current price of $0.96 — trading 77.6% below its estimated fair value. The current Interest Expense is $-0.18 Mil. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Interest Expense is $-0.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $0.96 is trading 77.6% below its estimated GF Value™ of $4.28. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

Interest Expense: $-0.18 Mil
GF Value™: $4.28 vs. price of $0.96 (77.6% below fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PDSB LTRN VERU TIL KALA IBO MGX HYPD APLM CNTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054

Website https://www.nuot.com

Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.

33GF Score

Get the complete analysis for AURX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96

Price

$4.28

GF Value

View AURX Analysis

See Interest Expense data for all stocks →